 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 142
Date: January 3, 2024
In a recent article (Sons of Rituxan and Campath) we reviewed the background for the Phase-2 clinical trial of GenMab’s new HuMax-CD20 monoclonal antibody. Like its more famous cousin Rituxan, this new monoclonal antibody also targets the CD20 marker on CLL cells. The high profile of this clinical trial was reflected in how fast the patient recruitment happened. The trial was sold out in record time, and several of our members were disappointed at not being able to get in.
ASH2005 had a paper on the preliminary results of this important clinical trial. Our analysis of the results is in a new article: Early Results from GenMab's HuMax Clinical Trial. As I am fond of saying, the devil is in the details - which we will track as additional results are reported from this trial.
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
